objective Cutaneous leishmaniasis (CL) receives far less attention than visceral leishmaniasis. Nevertheless, CL is predominantly caused by a unique species in Ethiopia (L. aethiopica), which is known to cause severe forms such as diffuse (DCL) and mucocutaneous leishmaniasis (MCL). We report on the number and type of CL cases diagnosed, the clinical features, the treatments and treatment outcomes in North-West Ethiopia.
Introduction
Cutaneous leishmaniasis (CL) is a protozoan disease predominantly occurring in tropical and subtropical countries. The disease is transmitted by sandflies and caused by different Leishmania species. While CL in the Old World is mainly caused by Leishmania (L) tropica and L. major, several ten thousands of cases are due to L. aethiopica [1] . These predominantly occur in Ethiopia, and the annual burden is estimated to be around 20 000 to 40 000 cases [2] , mainly occurring in the highland regions. Current reports suggest the clinical manifestations of L. aethiopica to be diverse. While localised CL (LCL) is the most frequent presentation, mucocutaneous (MCL) appears to be common as well [3] . Baring a few exceptions, L. aethiopica is the only species causing diffuse CL (DCL) in the Old World [4] . DCL is notorious for its chronic and progressive course and nonresponsiveness to the common antileishmanial drugs. Although not fatal like VL, CL is a chronic disfiguring condition that is much more common than VL and has a high social stigma.
As its occurrence is restricted mainly to Ethiopia and few of the other East African countries with limited resources, research on L. aethiopica has been relatively scarce. In terms of treatment of L. aethiopica, the evidence base remains extremely limited. A recent systematic review confirmed that many treatments had been used, but few had been properly evaluated [5] . The lack of evidence for proper guideline development is emphasised in the national guidelines, which prioritise clinical trials evaluating the currently available antileishmanial drugs in the country for CL treatment [6] . The currently available antileishmanial drugs include antimonials which are widely available, and paromomycin, miltefosine and liposomal amphotericin B. Liposomal amphotericin B is often reserved for severely sick, immune compromised and elderly patients. These antileishmanial drugs are made available in Ethiopia through support from international organisations such as the World Health Organization (WHO), the Drugs for Neglected Diseases initiative (DNDi) and M edecins Sans Fronti eres (MSF) to the VL treatment programmes. CL patients are treated in the health facilities that obtained antileishmanial drugs through VL programmes and are not priority. In general, there is no dedicated programme for CL but it is rather dependent on programmes for VL, which by itself is a neglected disease.
Several knowledge gaps need to be filled to be able to move towards clinical trials on the treatment of CL. First, the burden of patients presenting with CL to the major treatment sites needs to be quantified. Second, more information is needed on the clinical characterisation and type of CL and the treatment response. Using routinely collected data from the main leishmaniasis treatment and research centre in Northern Ethiopia, we report on the number and type of CL cases diagnosed, the clinical features and the initial and end of treatment outcomes.
Methods

Ethics statement
Ethical approval for the use of retrospective data was obtained from the institutional review board of the University of Gondar. Charts were reviewed by the treating physician. The pictures were taken from image archives of the Leishmaniasis Research and Treatment Center (LRTC). Images of the lesions are routinely photographed for treatment monitoring purposes, and patients are asked written approval to use their image for teaching and research purposes. The patients' data were handled confidentially by the treating physicians who are also the authors this manuscript.
Study setting
The study was conducted at the Leishmania Research and Treatment centre (LRTC) at the University of Gondar, located in North-West Ethiopia. There are several CL endemic districts in the catchment area. LRTC was established with the support of the Drugs for Neglected Diseases Initiative (DNDi). While it mainly acts as a clinical trial site for visceral leishmaniasis (VL) trials, it also provides routine treatment for VL and CL patients presenting outside of the studies. First-line VL treatment is antimonials combined with paromomycin. Liposomal amphotericin B (AmBisome) is available in limited amounts and is used for VL-HIV coinfection or severe VL cases (patients with organ dysfunction, oedematous and elderly). As increasingly patients with CL present for care at the centre, the available VL drugs are also used to treat CL patients. Due to scarcity of drugs, priority is, however, given to VL patients, as this condition can be potentially fatal. Services are provided for free by welltrained nurses, pharmacist, laboratory technologists and physicians. Clinical information on all VL and CL cases is systematically collected using standardised data collection forms.
Study design and population
We conducted a retrospective analysis of the medical record of all patients with a clinically and/or parasitologically confirmed diagnosis of CL attending LRTC between January 2014 and December 2015.
CL diagnostic and treatment practices
Slit skin smears are prepared for clinically suspected CL cases, and Giemsa stained smears are examined microscopically for the presence of Leishman-Donovan bodies (parasitological diagnosis). Systemic treatment of CL is recommended in case of multiple lesions, lesions on the face or other cosmetic sites, immunosuppression, MCL and DCL [7] . Antimonials are the commonly available drugs for CL treatment in Ethiopia. At LRTC, sodium stibogluconate 20 mg/kg IV/IM per day for 30 days is used. Other antileishmanial drugs are used if available and indicated. This includes intralesional antimonial injection, liposomal amphotericin B (AmBisome), paromomycin and cryotherapy. Patients may receive treatment as inpatients or they may be linked to their nearby health centre with the drugs and instructions of treatment and a follow-up plan. The initial outcome, as judged by the treating physician, is assessed clinically or parasitologically after one month of treatment. Initial treatment outcome is categorised as follows:
• Cure (complete resolution): complete healing of the lesion (re-epithelisation of an ulcer; flattening and disappearance of inflammation of nodular lesions).
• Partial response: any reduction in size and induration/ inflammation of the lesion.
• No response: no change in size and induration/inflammation of the lesion at all.
In case of no or partial improvement, a treatment extension or change is performed for at least two additional weeks.
Case definitions
The clinical assessment of the different types of CL is made depending on the type, location and number of lesions (see Box 1) . For the purpose of this study, the diagnosis of CL referred to patients suspected of CL with either parasitological confirmation or a strong clinical suspicion if a parasitological test was negative or not performed and physician's decision to treat as CL and the treatment response. Papular, nodular or ulcerative lesions were noted and used to make a clinical diagnosis of LCL.
The maximum length and width of the lesion was measured which may be ulcer, induration or patch. In case of multiple lesions, the size of the biggest lesion was measured to help follow treatment response. Patients with multiple or extensive nodular lesions, often bigger in size than those of LCL patients and usually involving multiple body sites were identified as DCL. MCL referred to the concurrent presence of CL with lesions involving the mucosa, either separate or via a skin lesion crossing the mucosal barrier.
Data collection and analysis
The sociodemographic information (sex, age, occupation and region), clinical assessment (duration of illness, type of lesion, number of lesions and location, comorbidities, previous treatment used), laboratory results (parasitologic and HIV testing) treatment details and response were collected. Data were entered in a clinical record form and stored electronically. Data were analysed with Epi Info. version 3.5.3 and STATA version 14 (STATACorp LP, College Station, USA).
Results
Between January 2014 and December 2015, a total of 178 patients were diagnosed with CL at the LRTC. Of these, 154 of the charts were retrieved and analysed. The median age was 23 years (interquartile range (IQR): 16-38), 71.4% were male and 26.6% were under 18 years of age (see Table 1 ).
There were 80 cases of LCL, 67 MCL and 7 DCL (see Figure 1 , e.g. of typical clinical presentations). The vast majority (n = 142; 92.2%) presented with primary CL (first diagnosis). In total, 83 (53.9%) had received treatment for their CL episode prior to presenting at the LRTC, most often traditional medicine (n = 44; 28.6%). The median (IQR) duration of lesion was 12 (6-24) months. Table 2 summarises the clinical features in terms of the number, size, type and distribution of the lesions.
The face was the most affected site (n = 121; 78.6%), predominantly on the nose, cheeks, chin, ears, forehead and/or lips. The most common features were induration, erythema, ulceration and crusty or patchy lesions.
Nineteen of the 154 CL patients were not treated, as drugs were in limited supply (n = 12), there was no indication (n = 5), due to pregnancy (n = 1) or for unknown reasons (n = 1). All but two of the 135 treated patients started treatment with systemic antimonials for 30 days. Of these, 51/133 (38.3%) required extension of treatment beyond one month. Figure 2 demonstrates the treatments and the outcomes for MCL and LCL cases.
All but one of the 59 treated MCL cases were initiated on antimonial treatment. Of the 35 cases with their end of treatment outcome ascertained, 11 (31%) were cured, 20 (57%) were partial responders and 4 (11%) were nonresponders. Of the 16 with outcomes ascertained after an SSG treatment extension, 12 (75%) got cured, three (19%) had a partial response and one (6%) failed to respond. All five HIV-coinfected MCL cases were treated with antimonials, of which three achieved cure, one a partial response and for one no outcome was recorded. There was one 71 year-old MCL case that was cured after treatment with intravenous AmBisome for a total dose of 2000 mg (5 mg/kg for 10 doses). Another ten-year-old MCL case that showed only partial response to intramuscular antimonials for 90 days was cured with the combination of AmBisome (total dose 920 mg; 5 mg/kg for eight doses) and miltefosine (100 mg/day for 28 days). An example of severe case of MCL is shown in Figure 1b .
All but one LCL case received antimonials as initial treatment but the initial treatment outcome was unknown in a substantial proportion of the patients. Among the 26 with treatment outcomes ascertained, five (19%) were cured at the end of treatment, 16 (61%) displayed a partial response and five (19%) failed to respond.
Of the seven DCL cases treated with antimonials (six for one month, one for 3.5 months), one was cured, five had a partial response and one failed to response. The nonresponder evolved to a partial response after two additional weeks of intramuscular antimonial and paromomycin combination therapy, intralesional antimonial and combination of AmBisome 12 doses of 5 mg/kg and miltefosine 100 mg for 28 days. One partial responder was cured by extension of treatment with antimonial and paromomycin combination for 17 days while another responded with 45 days more of systemic antimonial injection. The three remaining partial responders received a treatment extension with antimonials, after which one remained a partial responder. For the two others, the outcome was unknown.
Discussion
We report on a relatively high burden of severe or complicated CL in one of the leishmaniasis treatment centre in North-West Ethiopia. Most presented after a long duration of illness and use of traditional medicine. MCL was relatively common among the treated cases, diagnosed in 44%. Antimonials were the initial treatment in all but two cases. Of the 126 SSG-treated patients, only 17 (13.5%) had complete cure at the end of one month of treatment, and 51 (38.3%) required prolonged treatment beyond a month. We also report the first three cases of CL treated with AmBisome (two in combination with miltefosine) in Ethiopia.
Treatment response could only be assessed at the end of treatment, and not even in all patients. For some, this was due to recording errors, but for most this was because -depending on the availability of hospital beds -some of the patients were referred to a nearby health centre with the drugs and they do not come back for evaluation at the end of the treatment. Definite response, usually ascertained at three or six months after treatment, could thus not be determined [8] . While the relatively high proportion with complicated CL, requiring systemic treatment, could be related to the L. aethiopica species, other factors are likely to be involved. The limited diagnostic facilities and the need to travel long distances for treatment is one. With CL affecting poor communities, patients with less severe lesions are probably less likely to seek care. The stigma and discrimination of individuals with such lesions appearing on the face also keeps them hiding. The severity of the disease might also be due to the long duration before presentation. On the other hand, due to the limited availability of antileishmanial drugs, there is a trend to prioritise VL followed by severe CL cases. This might have created a bias on the community that CL will not be treated unless severe or complicated. Thus, presentation to the hospital may have selection bias. Finally, the nonremarkable treatment response with the existing treatments can also be a factor. Indeed, although most displayed a partial response to SSG treatment, only a minority got cured after one month of treatment. While this calls for more effective treatments, it needs to be realised that, particularly for severe or longstanding lesions, one month after treatment initiation is too early to expect cure. Treatment of CL at an early stage in the course of the lesion might be a better strategy to achieve better cure rates.
In line with other Ethiopian studies [3, 9] , MCL was relatively common, which could in part be due to its often dramatic clinical presentation and potentially marked stigmatisation, increasing the likelihood of patients seeking care. Until large-scale epidemiological studies have been conducted, the relative incidence of MCL (vs. CL) remains not well defined. We note that MCL in Ethiopia is different from the MCL described in Latin America, mainly due to L. braziliensis [1] . In that continent, lesions are thought to result from hematogeneous spread from the skin lesion, and mucosal lesions typically occur after the primary skin lesion. In our study, mucosal lesions were typically present together with the skin lesions and most often mucosal lesions expanded to the skin. Possibly, some of the MCL cases in our study are due to sandfly bites on or close to the mucosal barrier (e.g. bites on the lips) [10] . Slow and poor response was observed among the MCL and DCL patients. One MCL and one DCL cases required prolonged treatment (more than three months) showing only partial response to antimonials. Such decisions of prolonged treatment might have been made when patients were tolerating and showing partial response to antimonials, but that there was no alternative option for the physician by then to modify their treatment. We also report on the first three CL patients treated with liposomal amphotericin B or liposomal amphotericin B with miltefosine, who responded well after failing to cure on prolonged SSG treatment. They were as follows: a 71-year-old MCL patient who received liposomal amphotericin B from the start; a 10-year-old MCL patient who did not respond after 90 days of antimonial injection and was treated with AmBisome plus miltefosine; and one of the seven DCL patients who failed to respond to antimonials who was finally treated with liposomal amphotericin B plus miltefosine. While the good response in the LCL and MCL case is encouraging, larger studies are obviously needed. Liposomal amphotericin B has been found effective against mucosal leishmaniasis in the New World [11] , and miltefosine has been found effective against L. aethiopica in vitro [12] . However, it should be remembered that in addition to the clinical indication to use these medicines, such as the age of the patients and severity of illness, the availability of the medicines in stock at the treatment sites is a critical factor.
Our findings lead to a number of important implications and recommendations. First, epidemiological studies are required in Ethiopia to obtain precise estimates of the CL burden. A recent study on mapping of CL risk areas could be useful to identify priority regions [13] . Next, a plan for reinforcing CL diagnostic and treatment services in the affected regions should be developed. Given the poor evidence based for CL treatment in Ethiopia, capacity and plans to conduct clinical trials in these areas should be integrated from the onset. As to the treatment of complicated CL, priority drugs to be evaluated have been identified for Ethiopia. An international workshop organised by the Armauer Hansen Research Institute (AHRI) & WHO was held in Addis Ababa in 2011, to identify the major priorities and research gaps related to treatment of Ethiopian CL [7] . A key recommendation was that 'there is an urgent need for trials to evaluate the relative merits of paromomycin, miltefosine and liposomal amphotericin B in the treatment of CL in Ethiopia', and this has again been emphasised in the national guidelines [6] . These drugs were prioritised as they are currently available for VL treatment in the country, and hence, evaluations in clinical trials could thus proceed quickly. Other drugs with potential use for CL treatment either alone or in combination that needs to be explored include pentamidine, -azoles and allopurinol [5] .
For noncomplicated CL, cryotherapy and intralesional SSG are the treatment options in Ethiopia. Thermotherapy should also be evaluated as cheap and easy to use techniques are currently available, which look promising in studies conducted on other CL species [14] .
The diverse clinical presentation is likely to complicate evaluation of therapeutic interventions in clinical trials. The efficacy of drugs might depend on the type of lesions, which would call for stratified randomisation. This would require sound classification of different kind of presentations in comparable groups. As the clinical presentation of CL in Ethiopia is very diverse, it remains unclear whether the current classification in CL, MCL and DCL is sufficiently refined and whether only relying on clinical parameters is sufficient. As immunological factors are likely to be critically involved in the clinical presentation and the response to treatment, immunological studies should be integrated in clinical research projects. The combination of clinical features and immunological markers might lead to a more comprehensive assessment, a refined classification of CL and might also explain the variability in treatment response observed in clinical practice. Immunological studies could contribute to clinically useful prognostic biomarkers that can guide the optimal treatment across the pattern of disease manifestations and severity. Ultimately, immunological classification of cases might also allow identifying patients that might benefit from approaches aiming for immunological enhancement. For instance, DCL is considered an anergic form which poorly responds to chemotherapy and adjuvant immunotherapy would be an interesting avenue to explore [15] [16] [17] [18] .
Box 1 Definitions of the various clinical forms of cutaneous leishmaniasis caused by Leishmania aethiopica
LCL: Nodular or indurated lesion which may have ulcerated at the center, with a raised and erythematous edge around it. There may be several of these lesions close to each other, and they may spread into each other to form one large lesion. It may heal with a scar. MCL: Lesions marked by involvement of naso-oral and pharyngeal mucosa. These can often be destructive and mutilating causing difficulties in eating and drinking. DCL: This is a chronic, progressive condition that starts with few papular or nodular lesions followed by a gradual dissemination of the infection leading to multiple papular, nodular and plaque lesions involving larger areas of the skin that often do not ulcerate. Lesions are polyparasitic and resemble lepromatous leprosy.
LCL: localized cutaneous leishmaniasis (CL); MCL, mucocutaneous leishmaniasis; DCL, diffuse CL.
The study limitations have to be realised. This was a single-centre study focusing on severe and complicated CL cases. There is thus limited information on less severe forms that probably often remain undiagnosed. In addition, information on the treatment responses was not available for a substantial number of patients. The lack of a control group complicates the interpretation of the treatment response.
Our findings are likely only the tip of the iceberg as less severe forms are probably under-reported. To enhance case finding, community education and information campaigns are important. This would require strengthening diagnostic and treatment facilities to cope with the increasing demand. Enhanced healthcare seeking would also allow organising large clinical trials to construct the evidence base for rational treatment of CL due to L. aethiopica. Lesions were highly diverse and pleotropic, which would complicate evaluation of therapeutic interventions. Adding immunological parameters to better classify the different type of presentations might be required.
